Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 3/20 | 0.82 |
| ▸ | ACHE | P22303 | 1/20 | 0.82 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uric Acid SCHEMBL3669633 | 0.92 | GDA (0.70) | GDAACHEALDH1A1PNP | |
| Xanthine SCHEMBL4965 | 0.91 | GDA (1.00) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL2352524 | 0.91 | GDA (1.00) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL29669592 | 0.91 | GDA (1.00) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL2454001 | 0.89 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL1507586 | 0.89 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL7044227 | 0.89 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL6783299 | 0.89 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL7044230 | 0.89 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL31048830 | 0.89 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0100217-B1 | PROCESS FOR QUANTITATIVE DETERMINATION OF SUBSTRATE TREATED WITH OXIDASE | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1987-10-07 | — | — | EP | claimed |
| EP-3808353-B1 | COMPOSITION AND USE OF AN OPHTHALMIC SOLUTION BASED ON HYALURONIC ACID AND ARABINOGALACTAN | MD ITALY SRL (IT) | 2023-08-16 | — | — | EP | disclosed |
| US-20230173032-A1 | Treatment of Hyperuricemia | FREDERIKSBERG HOSPITAL (DK) | 2023-06-08 | — | — | US | disclosed |
| EP-4146221-A1 | TREATMENT OF HYPERURICEMIA | Frederiksberg Hospital (DK) | 2023-03-15 | — | — | EP | disclosed |
| WO-2021224338-A1 | TREATMENT OF HYPERURICEMIA | FREDERIKSBERG HOSPITAL (DK) | 2021-11-11 | — | — | WO | disclosed |
| EP-3808353-A1 | COMPOSITION AND USE OF AN OPHTHALMIC SOLUTION BASED ON HYALURONIC ACID AND ARABINOGALACTAN | MD Italy Srl (IT) | 2021-04-21 | — | — | EP | disclosed |
| CN-110461364-A | Medicaments and uses for treating cancer and other pathological conditions associated with aging | TAS SINAN | 2019-11-15 | — | — | CN | disclosed |
| CN-108351920-A | System and method for obtaining test result from body sample | 生物检测有限公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-106929591-A | A kind of human HLA B*5801 genetic polymorphism detection kits | 武汉友芝友医疗科技股份有限公司 | 2017-07-07 | — | — | CN | disclosed |
| US-9107912-B2 | Methods for concomitant treatment of theophylline and febuxostat | TAKEDA PHARMACEUTICALS U.S.A., INC. (US) | 2015-08-18 | — | — | US | disclosed |
| WO-2012131411-A1 | METHOD FOR COLORIMETRIC DETERMINATION OF cPNMP SPECIFIC ENZYME ACTIVITY VIA COUPLED ENZYMATIC REACTIONS | SEMMELWEIS EGYETEM (HU) | 2012-10-04 | — | — | WO | disclosed |
| CN-101816630-B | Uricase lipid nanoparticle and preparation method thereof | UNIV CHONGQING MEDICAL | 2012-07-04 | — | — | CN | disclosed |
| US-20120065236-A1 | METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT | TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065215-A1 | METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT | TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065207-A1 | METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT | TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2011091299-A1 | COMPOSITION FOR PERINATAL AND NEONATAL STROKE | ADDIS PAUL BRADLEY (US) | 2011-07-28 | — | — | WO | disclosed |
| CN-101982115-A | Composite for preventing and curing diabetes chronic sugar poisoning | LINA ZHANG | 2011-03-02 | — | — | CN | disclosed |
| CN-101816630-A | Uricase lipid nanoparticle and preparation method thereof | CHONGQING UNIVERSITY OF MEDICAL SCIENCES | 2010-09-01 | — | — | CN | disclosed |
| CN-101417119-A | Pharmaceutical composition and package for rapidly reducing uric acid in blood and application of anserine to rapidly reducing uric acid in blood | LYTONE ENTERPPRISE INC (CN) | 2009-04-29 | — | — | CN | disclosed |
| CN-1600854-A | Novel diatom manganese type superoxide dismutase and its use | YISHENG BIO TECH DEV CO LTD (CN) | 2005-03-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065215-A1 | METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT | XDH, HPRT1, TPMT | GDA 550/4885ACHE 1159/4885ABL1 2880/4885 |
| US-20120065207-A1 | METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT | XDH, HPRT1, TPMT | GDA 550/4885ACHE 1159/4885ABL1 2880/4885 |
| US-20120065236-A1 | METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT | XDH, HPRT1, TPMT | GDA 550/4885ACHE 1159/4885ABL1 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.